About 415 CAPITAL
415 CAPITAL is a venture capital firm founded in 2018. It is primarily based out of Oberhaching, Germany. As of Sep 2026, 415 CAPITAL is an active investor, having invested in 29 companies, with 1 new investment in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series A round of ReEmerge Overall, 415 CAPITAL portfolio has seen 1 unicorn, 1 IPO and 12 acquisitions including key companies like Acorns, Endologix and ReCor Medical. A lot of funds co-invest with 415 CAPITAL, with names like Wellington Partners Venture Capital sharing a substantial percentage of its portfolio. 415 CAPITAL has team of 12 people including 6 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 3 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Deals in last 12 months
415 CAPITAL's List of Top Investments
415 CAPITAL has a portfolio of 29 companies, one of which is a Unicorn. Their most notable investments are in R3 Vascular and Moray Medical.Their portfolio spans across United States, Switzerland and Germany. They have invested in Life Sciences, High Tech, Enterprise Applications and 3 other sectors, across stages such as Series A, Series B and 3 more. Here is the list of top investments by 415 CAPITAL:1. Acorns
App-based platform for spare change investment. The company allows users to collect spare change from everyday transactions. It rounds off the user's transactions to the nearest dollar and invests it. It also gives customers discretion over the type of portfolio they want to create, with five alternatives to pick from. It also provides money-saving education tools.
Key facts about Acorns
2. Hilo
Provider of continuous blood pressure monitoring devices and associated app. The device tracks blood pressure twenty-four hours a day, providing comprehensive data and insights. This allows users to identify patterns and trends in their blood pressure, understand the impact of lifestyle factors, and share this information with healthcare providers. The accompanying app offers personalized support and facilitates informed decision-making regarding health management.
Key facts about Hilo
- Founded Year: 2018
- Location: Neuchatel (Switzerland)
- Stage: Series B
- Total Funding till date: $119M
- Employee Count: 85 as on Aug 31, 2026
- Investors: Spark Capital, Earlybird and 14 Others
- Latest Funding Round: Series B, Jul 21, 2026, $*****
- Highlight: Editors' Pick
3. Endologix
Endologix develops and manufactures minimally invasive treatments for aortic disorders. Endologix’s flagship product is the Powerlink System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. It acquired Nellix, a developer of medical devices for the minimally invasive treatment of aortic aneurysms.
Key facts about Endologix
- Founded Year: 1992
- Location: Irvine (United States)
- Stage: Public
- Employee Count: 503 as on Sep 30, 2026
- Investors: Deerfield, North Bay Angels and 4 Others
- Latest Funding Round: Conventional Debt, Apr 04, 2019, $*****
- Highlight: Public
Developer of ventricular assist devices for coronary intervention and cardiogenic shock. The company has developed solutions for temporary mechanical circulatory support percutaneous ventricular assist devices. It has a feature that maintains the native pumping action of the heart. It provides real-time data about pump performance and location and minimizes vascular complications for patients with coronary artery disease.
Key facts about Supira Medical
- Founded Year: 2016
- Location: Campbell (United States)
- Stage: Series E
- Total Funding till date: $240M
- Employee Count: 143 as on Sep 30, 2026
- Investors: Qatar Investment Authority, Techlink Ventures and 9 Others
- Latest Funding Round: Series E, Mar 25, 2025, $*****
- Highlight: Editors' Pick
5. Distalmotion
Developer of robotic devices for surgical procedures. It develops DEXTER, a hybrid surgical robot that simplifies robotic-assisted minimally invasive surgery for hospitals and outpatient settings. It consists of fully articulated, single-use 8 mm instruments for suturing and dissection, like needle drivers, Johann graspers, monopolar scissors, and bipolar Maryland forceps. The device also provides the option to switch between laparoscopic and robotic surgery at any time during surgery.
Key facts about Distalmotion
- Founded Year: 2012
- Location: Epalinges (Switzerland)
- Stage: Series G
- Total Funding till date: $390M
- Employee Count: 219 as on Sep 30, 2026
- Investors: Zühlke, EuroUS Ventures and 10 Others
- Latest Funding Round: Series G, Jan 12, 2026, $*****
- Highlight: Editors' Pick
415 CAPITAL's Year-on-Year Investment Trends
415 CAPITAL has invested in 29 companies over the last 6 years, with an average of 1 new investment annually in the last 5 years. In 2025, it made 2 investments, while as of Sep 2026, it has made 2 investments in this year. Its most recent first time investment was in ReEmerge and most recent follow-on round was in Endovascular Engineering.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 1 | 2 |
2025 | 1 | 1 | 2 |
2024 | 1 | 2 | 3 |
2023 | 0 | 1 | 1 |
2022 | 2 | 1 | 3 |
2021 | 3 | 0 | 3 |
2020 | 2 | 0 | 2 |
415 CAPITAL's Investments by Stage
415 CAPITAL has made 4 investments in Series A stage with an average round size of $19.4M, 3 investments in Series B stage with an average round size of $41.9M, 1 investment in Seed stage with an average round size of $5.7M, 1 investment in Series C stage with an average round size of $52.8M and 1 investment in Series E stage with an average round size of $90M.Stage of entry | No. of Investments |
|---|---|
Series A | 4 |
Series B | 3 |
Seed | 1 |
Series C | 1 |
Series E | 1 |
Note: We have considered here, only first round of investments
415 CAPITAL's Investments by Sector
415 CAPITAL has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Robotics - Industry Applications, HealthTech and Healthcare. Notably, it has invested in 24 Tech companies, 23 Enterprise (B2B) companies, 14 Tech hardware companies and at least 7 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 8 |
High Tech | 2 |
Robotics - Industry Applications | 2 |
HealthTech | 1 |
Healthcare | 1 |
Note: We have considered here, only first round of investments
415 CAPITAL's Investments by Geography
415 CAPITAL has made most investments in United States (5), followed by Switzerland where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 5 |
Switzerland | 3 |
Germany | 1 |
Note: We have considered here, only first round of investments
415 CAPITAL's recent investments
415 CAPITAL has made 2 investments in 2026 so far - ReEmerge and Endovascular Engineering.Here are the most recent investments by 415 CAPITAL:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 15, 2026 | - | Series A | 7929 | [+4] | |
Apr 07, 2026 | United States | Series C | 6665 | [+5] | |
Mar 25, 2025 | United States | Series E | 6005 | [+6] | |
Feb 18, 2025 | United States | Series B | 8422 | [+3] | |
Sep 10, 2024 | Switzerland | Series B | 1125 | [+8] |
Unicorns in 415 CAPITAL's Portfolio
415 CAPITAL has 1 unicorn in its portfolio - Acorns. The most recent unicorn in their portfolio is Acorns which became a unicorn in 2019, 7 years before 415 CAPITAL first invested in it.Here is a list of unicorns in 415 CAPITAL's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
78 | App-based platform for spare change investment | 2012 | Irvine | Series F | xiklgjh |
IPOs and Publicly Listed companies in 415 CAPITAL's Portfolio
1 of 415 CAPITAL's portfolio company became public - Endologix. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 1996.Here are 415 CAPITAL's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 28, 1996 | - | - | 9779 |
Acquired companies in 415 CAPITAL's Portfolio
12 companies from 415 CAPITAL's portfolio have been acquired. The most recent acquisition was Intact Vascular in Aug 2020 by Philips for $*****.Here are 415 CAPITAL's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 27, 2020 | - | - | 3100 | |
Sep 09, 2019 | - | - | 4746 | |
Oct 04, 2018 | - | - | 3371 | |
Jul 20, 2018 | - | - | 8874 | |
Jul 10, 2018 | - | - | 9147 |
Team profile of 415 CAPITAL
415 CAPITAL has a team of 12 members including 6 Partners and 1 Principal located in Germany and United States. 415 CAPITAL's team sits on the board of 1 company.Here is a list of top team members in 415 CAPITAL:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Partner | Munich | - | - | |
Partner | - | - | - | |
Partner | Oberhaching | - | - | |
Partner | - | - | ||
Partner | Munich | - | - | |
Principal | Berlin | - | - |
Co-investors of 415 CAPITAL
Over the past 6 years, 63 investors have co-invested in 415 CAPITAL's portfolio companies. This includes funds and angels.
- Invested before 415 CAPITAL: EIC Fund, Redalpine and 14 others have invested in rounds before 415 CAPITAL. There are 2 companies where EIC Fund has invested before 415 CAPITAL and 1 company where Redalpine has invested before 415 CAPITAL.
- Top Co-investors of 415 CAPITAL: 29 investors entered a company along with 415 CAPITAL. These include investors like Wellington Partners Venture Capital (2 companies).
- Invested after 415 CAPITAL: A total of 18 investors have invested in 415 CAPITAL's portfolio after their investments. Top Investors include Earlybird (1 company), Wellington Partners Venture Capital (1 company) and K Fund (1 company).
Recent News related to 415 CAPITAL
•
•
Supira Medical raises $120M in Series E funding, completes US feasibility study.PR Newswire•Mar 26, 2025•Supira Medical, Novo Holdings, Sidley, Piper Sandler and 7 others
•
Endovascular Engineering Raises $42 Million in Series B Financing to Advance the Treatment of Pulmonary EmbolismPR Newswire•Feb 18, 2025•Endovascular Engineering, 415 CAPITAL, S3 Ventures, M&L Healthcare and 3 others
•
CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack PatientsFinancial Post•Sep 10, 2024•Corflow, Broadview Ventures, Panakes Partners, 415 CAPITAL and 9 others
•
TRiCares raises $50m to trial tricuspid heart valve replacement systemclinicaltrialsarena.com•Jul 25, 2024•TRiCares, 415 CAPITAL, Andera Partners, Bayern Kapital and 5 others
•
R3 Vascular Gains New Funding And New CeoMedical Product Outsourcing•Jul 15, 2024•R3 Vascular, 415 CAPITAL
•
R3 Vascular raises $87M to test its bioresorbable scaffold for blocked arteries below the kneeFierce Biotech•May 17, 2024•R3 Vascular, Deerfield, 415 CAPITAL
•
R3 Vascular Announces $87 Million in Series B FinancingMedical Device News•May 09, 2024•R3 Vascular, Deerfield, 415 CAPITAL
•
Aktiia, Optical Health Monitoring Firm, Gains $30M in FundingPhotonics Media•Feb 29, 2024•Aktiia, Redalpine, Khosla Ventures, molten and 8 others
•
Supira Medical Closes $40M In Series D FinancingFinSMEs•Nov 22, 2023•Supira Medical, Cormorant Asset Management, The Capital Partnership, 415 CAPITAL and 2 others
